The settlement removes patent litigation overhang and provides clarity on generic entry timing (Sept 2030). Monitor FTC/DOJ review outcome and any potential impact on Jelmyto revenue trajectory. The 4+ year runway to generic entry is a modest positive for Jelmyto's commercial outlook.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $26.54entry
- T+1 · 6mo ago +0.23%α +0.92% · $26.60
- T+5 · 5mo ago +6.18%α +9.14% · $28.18
- T+20 · 5mo ago +42.95%α +44.52% · $37.94
- T+60 · 3mo ago +73.10%α +71.98% · $45.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlement, UroGen grants Teva a non-exclusive license to sell a generic version beginning September 15, 2030, if FDA-approved. The agreement resolves all ongoing patent litigation in the U.S. District Court for the District of Delaware and is subject to FTC/DOJ review.
Key Facts
- UroGen entered a settlement and license agreement with Teva resolving patent litigation over Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva will receive a non-exclusive license to sell its generic version of Jelmyto beginning September 15, 2030, if FDA-approved.
- All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
- The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
- No financial terms of the settlement were disclosed in the filing.
Financial Impact
No financial terms disclosed. The settlement removes litigation uncertainty and establishes a generic entry date of September 15, 2030, which is approximately 4+ years from now.
Risk Factors
- FTC or DOJ could challenge or modify the settlement terms.
- Earlier generic entry if certain limited customary circumstances occur.
- No financial terms disclosed, potential undisclosed royalty or payment structure could alter the economic impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index-headers.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102.txt | 0001437749-26-019102 |
Track record
16 reports on URGN
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers